J&J’s Rybrevant and Talvey Win Separate NMPA Approvals in China
US pharma giant Johnson & Johnson (J&J, NYSE: JNJ) announced receiving marketing approvals from China’s...
Company
Degron Therapeutics’ DEG6498 Receives FDA Clearance for Clinical Trials
China-based Degron Therapeutics, a developer of molecular glue-based drugs, announced that the U.S. Food and...
Roche Transfers InterMune and Esbriet to Legacy Pharma in IP Deal
Swiss pharma giant Roche (SWX: ROG) has transferred US-based InterMune, Inc., acquired for USD 8...
Bio-Thera Solutions’ BAT1006 Wins NMPA Approval for HER2+ Breast Cancer Trial
China’s Bio-Thera Solutions Ltd (SHA: 688177) has received clinical trial approval from the National Medical...
China Resources Double-Crane Pharmaceutical Co., Ltd Receives NMPA Approval for Generic Purinethol
China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) announced that it has received marketing approval...
Henlius Biotech’s HLX99 Receives FDA Approval for ALS Clinical Study
Shanghai Henlius Biotech Inc. (HKG: 2696) announced that the U.S. Food and Drug Administration (FDA)...
Henlius Biotech Doses First Patient in HLX43 Phase II Study for Esophageal Cancer
Shanghai Henlius Biotech Inc. (HKG: 2696) announced the first patient dosing in a Phase II...
Bayer Files for Eylea 8 mg EMA Approval to Extend AMD, DME Treatment Intervals
Bayer (ETR: BAYN) has submitted a marketing application to the European Medicines Agency (EMA) for...
Bristol-Myers Squibb’s Breyanzi Hits Primary Endpoint in Lymphoma Study
Bristol-Myers Squibb (BMS, NYSE: BMY) reported positive results from the Phase II TRANSCEND FL study...
CSPC Pharmaceutical’s SYH2039 Wins FDA Clinical Approval for Advanced Tumors
China’s CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that the U.S. Food and Drug Administration...
Boehringer Ingelheim’s Nerandomilast Hits Primary Endpoint in PPF Phase III Study
German pharma giant Boehringer Ingelheim announced positive topline results from the Phase III FIBRONEER-ILD study...
CSPC Pharmaceutical’s Omalizumab Biosimilar Wins NMPA Approval for Allergic Asthma
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has received an additional indication approval from the...
Kelun-Biotech to Present SKB264/MK-2870 Data for Urothelial Carcinoma at ASCO-GU 2025
China’s Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) will present efficacy and safety data from...
Sinopep-Allsino Wins NMPA Approval for Generic Liptruzet in China
Jiangsu-based CDMO Sinopep-Allsino Biopharmaceutical Co., Ltd (SHA: 688076) has received marketing approval from China’s National...
R-Nanoablation Raises USD 13.7M in Series B+ to Advance Nanosecond Ablation Tech
Hangzhou-based R-Nanoablation, a minimally invasive medical device developer, has raised over RMB 100 million (USD...
Bio-Thera Solutions Licenses BAT2506 to Intas Pharmaceuticals for US Market
China-based Bio-Thera Solutions Inc. (SHA: 688177) announced that it has entered into a licensing agreement...
Changchun GeneScience’s GenSci120 Receives NMPA Approval for Rheumatoid Arthritis Trials
China-based Changchun GeneScience Pharmaceutical Co., Ltd announced that it has received another clinical trial approval...
CARsgen’s Allogeneic BCMA CAR-T Therapy Achieves sCR in First Patient
China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced that the first patient treated with its...
Haisco Pharmaceutical Group Registers Delaware Subsidiary to Expand Global Operations
Shenzhen-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced the registration of a new...
Beijing Luzhu Submits BLA for LZ901 Herpes Zoster Vaccine to NMPA
Beijing Luzhu Biotechnology Co., Ltd (HKG: 2480), a human vaccine and therapeutic biologics manufacturer, announced...